Leukemia Clinical Trials in Chicago

Showing 601-620 of 821 trials

A Study for Patients With Acute Leukemia

NCT01214655

This study is a multicenter, nonrandomized, open-label, dose-escalation with intra-patient dose-escalation, Phase 1 study of intravenous LY2523355 to determine the dose of LY2523355 that can be safely administered to participants with acute leukemia. Part A and Part B are dose escalation of two schedules in participants with acute leukemia. Parts A and B will enroll concurrently. Part C is a dose expansion for each schedule in participants with acute myeloblastic leukemia (AML).

Acute Leukemia

Eli Lilly and Company33 participantsStarted Jun 2008

Chicago, Illinois, United States • Indianapolis, Indiana, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDPHASE12.2 miles

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

NCT00586924

A dose-escalation study to identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), defined as the highest dose that can safely be given to a participant and establish the safest dose based on the highest tolerated dose for clinical testing.

Hairy Cell Leukemia

MedImmune LLC49 participantsStarted May 2007

Stanford, California, United States • Chicago, Illinois, United States • Bethesda, Maryland, United States +1 more locations

A Study for Patients With Acute Leukemia

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Leukemia Trials in Other Cities

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Early Diagnosis of Candidiasis in Premature Infants

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Immunogenicity of PCV-7 Vaccine in VLBW Infants

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Comparability and Standardization of Controlled Allergen Challenge Facilities

Other Conditions in Chicago